← Leaderboards
Ruijie Liu
Icahn School Of Medicine At Mount Sinai
$1,461,928
Attributed
$2,923,856
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $589.5K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,923,856 · 1
By mechanism
R01$2,923,856 · 1
Top collaborators
- John C He5 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Julie Wang$678,795
- Eric J Nestler$73,310,132
- Roger J. Hajjar$21,947,839
- Robert J Devita$8,217,526
- Madhavika Niroshini Serasinghe$576,000
Others in their field
Other Emerging Leaders on “Actins”
- Baoyu Chen · Iowa State University$4,436,758
- Rose Ellen Dixon · University Of California At Davis$4,048,844
- Madhav C Menon · Yale University$3,449,144
- Michael R Ruff · Creative Bio-Peptides, Inc.$3,448,503
- Paul Blum · Neurocarrus, Inc.$3,021,555
- Nicolas Daniel Plachta · University Of Pennsylvania$3,013,538
Research focus
ActinsDisease ProgressionAdhesionsAlbuminuriaAffectAttenuatedAffinityBindingBinding ProteinsBiologyArctigeninCell AdhesionCellsChinaChinese HerbsChronic Kidney FailureCytoskeletonDb/Db MouseDiabetes MellitusDiabeticDiabetic MouseDiabetic NephropathyDifferential ExpressionDocking
Grant awards (5)
PP2A as a drug target for diabetic kidney disease$565,908
R01 · FY2024 · DK
PP2A as a drug target for diabetic kidney disease$589,487
R01 · FY2023 · DK
PP2A as a drug target for diabetic kidney disease$589,487
R01 · FY2022 · DK
PP2A as a drug target for diabetic kidney disease$589,487
R01 · FY2021 · DK
PP2A as a drug target for diabetic kidney disease$589,487
R01 · FY2020 · DK